ArticleFrontiers in medicine2026
Control effect of dual-mechanism myopia control lenses on myopia in children and adolescents: a prospective, 12-month, non-randomized, parallel-controlled, and single-center trial protocol.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myopia has become an increasingly serious global issue. Preventing myopia and avoiding the risks of high myopia has become an important concern for children, adolescents and their parents. Dual-mechanism myopia control lenses (DMMCL) is a specialized design spectacle lens based on peripheral defocus theory and retinal contrast theory. Although the benefits of peripheral defocus lenses and retinal contrast-designed lenses (RCDL) in myopia prevention have been confirmed, whether the lenses integrating both two designs can effectively prevent further progression of myopia still requires further research. Purpose: To report the protocol of a clinical trial designed to evaluate the efficacy and safety of DMMCL vs. RCDL alone for slowing the progression of myopia among school-age children in China. The primary objective of this study is to evaluate whether DMMCL are equivalent to RCDL in controlling myopia progression. Method and analysis: This is a prospective, single-center, non-randomized, equivalence trial designed to compare the efficacy and safety of DMMCL vs. RCDL for controlling myopia progression in children aged 6-12 years over a 12-month period. The primary outcome is change in axial length (AL) from baseline to 12 months. We hypothesize that the two treatments are equivalent within a prespecified margin of ±0.15 mm. This study will enroll 120 myopic children, aged 6-12 years, with cycloplegic spherical equivalent (SE) ranging from -0.50 D to -6.00 D in both eyes. Eligible participants will be assigned to the DMMCL group ( Outcome: Primary outcomes: Twelve-month changes in AL Secondary outcomes: Twelve-month changes in SE from baseline and binocular visual function parameters. Other pre-specified outcomes Adaption and vision quality questionnaire results. Conclusion: The future findings of this trial are expected to provide valuable reference for optimizing myopia management strategies and may contribute to the evidence base that informs pediatric eye care policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.